Dr. Ballinger Shares Her Top News From ASCO 2024
Tarah Ballinger, MD, discusses what she considers to be the biggest developments from the 2024 ASCO Annual Meeting.
Breast cancer was a major area of development at this year's American Society of Clinical Oncology (ASCO) Annual Meeting. In particular, clinical trials of antibody-drug conjugates (ADCs) like trastuzumab deruxtecan (Enhertu; T-DXd) and sacituzumab govitecan (Trodelvy) offered significant insights into treatment options and sequencing for patients with breast cancer.
Tarah Ballinger, MD, is an associate professor of clinical medicine at Indiana University School of Medicine and the Vera Bradley Foundation Scholar in Breast Cancer Research, who specializes in breast medical oncology, shared her highlights from the 2024 ASCO Annual Meeting.
Transcription:
0:05 | I think in breast cancer this year, we're going to see a lot of updates from some of the different antibody-drug conjugates. I think these are great because there's going to be so many more options for our patients living with metastatic disease. The question and what I hope to hear in some of the discussions is how we're going to best sequence all of these different drugs so that we can ultimately improve outcomes for our patients.
Durability and Intracranial Efficacy Observed With T-DXd in HER2+ MBC
January 13th 2025During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed how the outcomes of the DESTINY-Breast03 and other trials impact treatment of metastatic HER2-positive breast cancer in the second article of a 2-part series.
Read More
Jhaveri Compares Safety and Duration of Adjuvant CDK4/6 Inhibitors in HR+ Breast Cancer
December 22nd 2024During a Case-Based Roundtable® event, Komal Jhaveri, MD, FACP, discussed dosing and toxicity concerns with the approved CDK4/6 inhibitor regimens used in the adjuvant setting for patients with hormone receptor–positive breast cancer.
Read More
